目的 探讨地奥心血康胶囊联合尼可地尔治疗冠心病心肌缺血的疗效。方法 选取天津市静海区医院在2015年7月-2016年7月收治的冠心病心肌缺血患者161例，随机分成对照组（80例）和治疗组（81例）。对照组口服尼可地尔片，1片/次，3次/d。治疗组在对照组的基础上口服地奥心血康胶囊，2粒/次，3次/d。两组患者均规律治疗6周。评价两组患者临床疗效，同时比较治疗前后两组患者ST段压低次数、心肌耗氧量和心肌缺血总负荷、N-末端脑钠肽前体（NT-proBNP）水平和不良反应差异。结果 治疗后，对照组和治疗组的总有效率分别为81.25%、97.53%；两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者ST段压低次数、心肌耗氧量和心肌缺血总负荷均明显降低（P<0.05）；且治疗组这些指标均明显低于对照组患者（P<0.05）。治疗后，两组NT-proBNP水平均显著降低，同组治疗前后差异有统计学意义（P<0.05）；治疗后，治疗组NT-proBNP水平明显低于对照组，两者比较差异具有统计学意义（P<0.05）。治疗期间，对照组不良反应发生率为16.25%，显著高于治疗组的4.94%，两组比较差异具有统计学意义（P<0.05）。结论 地奥心血康胶囊联合尼可地尔治疗冠心病心肌缺血具有显著的临床疗效，可显著改善患者心肌缺血的预后，具有一定的临床推广应用价值。

Objective To explore the clinical efficacy of Di'ao Xinxuekang Capsules combined with nicorandil in treatment of myocardial ischemia of coronary heart disease. Methods Patients (161 cases) with myocardial ischemia of coronary heart disease in Jinghai Hospital of Tianjin from July 2015 to July 2016 were randomly divided into control (80 cases) and treatment (81 cases) groups. Patients in the control group were po administered with Nicorandil Tabltes, 1 tablet/time, three times daily. Patients in the treatment group were po administered with Di'ao Xinxuekang Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy was evaluated, and the differences of ST segment depression times, myocardial oxygen consumption, total myocardial ischemia load, NT-proBNP levels, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 81.25% and 97.53%, respectively, and there were differences between two groups (P<0.05). After treatment, the ST segment depression time, myocardial oxygen consumption and total myocardial ischemia load in two groups were significantly decreased (P<0.05). These indicators in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the NT-proBNP in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the NT-proBNP level in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P<0.05). After treatment, the incidence of adverse reaction in the control group was 16.25%, which was significantly higher than 4.94% in the treatment group, and there were differences between two groups (P<0.05). Conclusion Di'ao Xinxuekang Capsules combined with nicorandil have significant clinical efficacy in treatment of myocardial ischemia of coronary heart disease, and can significantly improve the prognosis of myocardial ischemia, which has a certain clinical application value.